Recent 8-K filings for IMVT

• May 20, 2026, 7:14 AM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16

  IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.

• February 6, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Immunovant reports Q3 net loss of $110.6M; cash $994.5M; D2T RA trial fully enrolled

  Net loss $110.6M ($0.61/sh) for Q3 FY26; non-GAAP net loss $97.5M.

• December 12, 2025, 6:59 PM ET other material materiality 0.70 neutral item 8.01item 9.01

  Immunovant raises $550M via 26.2M share offering at $21.00/share

  Gross proceeds ~$550M from 26.2M shares priced at $21.00/share.

• December 11, 2025, 6:59 PM ET other material materiality 0.70 negative item 8.01

  Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines

  Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.

• November 21, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

  Immunovant CMO Michael Geffner departs; consulting through April 2026

  Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.

• November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M

  Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.

• September 3, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01item 8.01item 9.01

  Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment

  80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.

• May 29, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker

  Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.

• April 21, 2025, 7:59 PM ET leadership materiality 0.80 positive item 5.02item 7.01item 8.01item 9.01 ◈ executive_change ×6

  Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE

  CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.

• March 19, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction

  MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).

• February 6, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement

  Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.

• January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  Immunovant announces $450M PIPE at $20/share to advance pipeline

  Agreed to sell 22.5M shares at $20/share to three institutional investors, including Roivant Sciences.

• November 7, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 8.01item 9.01

  Immunovant announces five IND clearances for IMVT-1402 and plans to initiate registrational trials by March 2025

  Five INDs cleared for IMVT-1402 across therapeutic areas including Graves' disease and rheumatoid arthritis.

• September 9, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial

  High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.

• August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment

  Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.

• May 29, 2024, 7:59 PM ET earnings materiality 0.85 neutral item 2.02item 9.01

  Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025

  Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).

• February 12, 2024, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402

  Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.

• December 20, 2023, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%

  Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.

• November 28, 2023, 6:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C

  Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.

• November 9, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential

  Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.

• September 28, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements ×2

  Immunovant Prices $280M Public Offering; Roivant Commits $170M Private Placement

  Public offering of 7,370,000 shares at $38.00/share; gross proceeds ~$280.1M.

• September 26, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes

  Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.

• August 10, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023

  Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.

• May 22, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 8.01item 9.01 ◈ Earnings Releases ×2

  Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started

  Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.

• November 4, 2022, 7:59 PM ET other material materiality 0.65 positive item 2.02item 9.01 ◈ Earnings Releases

  Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M

  IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.

• October 4, 2022, 7:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01

  Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development

  Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.

• September 28, 2022, 7:59 PM ET other material materiality 0.80 positive item 7.01item 8.01item 9.01

  Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data

  IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.

• September 7, 2022, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023

  Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.

• August 5, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track

  Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.

• June 8, 2022, 7:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M

  FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.

• January 5, 2022, 6:59 PM ET other material materiality 0.75 neutral item 7.01item 9.01

  Immunovant provides Phase 3 update for batoclimab in myasthenia gravis

  Corporate webcast held Jan 5, 2022; presentation focuses on Phase 3 development of batoclimab.

• December 30, 2021, 6:59 PM ET regulatory materiality 0.75 positive item 7.01item 9.01

  Immunovant achieves FDA alignment to start Phase 3 trial for batoclimab in MG in 1H 2022

  FDA Division of Neurology 1 agreed to move forward; Phase 3 for batoclimab in myasthenia gravis starts 1H 2022.

• November 23, 2021, 6:59 PM ET other material materiality 0.60 neutral item 1.01

  Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab

  Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event other_material

16 positive 2 negative 32 neutral

source · IMVT on sec.gov